Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding, John P.H., Batterham, Rachel L., Calanna, Salvatore, Davies, Melanie, Van Gaal, Luc F., Lingvay, Ildiko, McGowan, Barbara M., Rosenstock, Julio, Tran, Marie T.D., Wadden, Thomas A., Wharton, Sean, Yokote, Koutaro, Zeuthen, Niels, Kushner, Robert F.·2021·New England Journal of Medicine
DOI 10.1056/nejmoa2032183

Cited by (1,089)

Items 401–500 of 1,089

  1. Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity
    Ashok Ainkaran Ganeshalingam, Nicolai Gundtoft Uhrenholt, Sidse Arnfred, Peter Gæde, Signe Wegmann Düring, Elsebeth Nylev Stenager, Nick Bünger, Andreas Kristian Pedersen, Niels Bilenberg, Jan Frystyk · 2025 · JAMA Psychiatry
  2. GLP-1 agonists: A review for emergency clinicians
    Long, Brit, Pelletier, Jessica, Koyfman, Alex, Bridwell, Rachel E. · 2024 · The American Journal of Emergency Medicine
  3. Progress in Pharmacotherapy for Obesity
    Yanovski, Susan Z., Yanovski, Jack A. · 2021 · JAMA
  4. Patents and regulatory exclusivities on GLP-1 receptor agonists
    Alhiary, Rasha, Kesselheim, Aaron S., Gabriele, Sarah, Beall, Reed F., Tu, S. Sean, Feldman, William B. · 2023 · JAMA
  5. Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
    Ryan, Donna H. · 2021 · Journal of Obesity & Metabolic Syndrome
  6. Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
    Malik, Mariam Elmegaard, Falkentoft, Alexander Christian, Jensen, Jesper, Zahir, Deewa, Parveen, Saaima, Alhakak, Amna, Andersson, Charlotte, Petrie, Mark C., Sattar, Naveed, McMurray, John J.V. et al. · 2023 · The Lancet Regional Health - Europe
  7. Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation
    Sandra Naaman, Sherry Shen, Meltem Zeytinoglu, Neil M. Iyengar · 2022 · The Journal of Clinical Endocrinology & Metabolism
  8. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
    Fatma Haddad, Ghadeer Dokmak, Maryam Bader, Rafik Karaman · 2023 · Life
  9. Glucagon‐like peptide‐1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta‐analysis
    Andrea Saglietto, Giulio Falasconi, Diego Penela, Pietro Francia, Arunashis Sau, Fu Siong Ng, Veronica Dusi, Davide Castagno, Fiorenzo Gaïta, Antonio Berruezo et al. · 2024 · European Journal of Clinical Investigation
  10. Revised definition of obesity in Asian Indians living in India
    Anoop Misra, Naval K. Vikram, Amerta Ghosh, Piyush Ranjan, Seema Gulati · 2025 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  11. Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs
    Le, Richard, Nguyen, Mau T., Allahwala, Momina A., Psaltis, James P., Marathe, Chinmay S., Marathe, Jessica A., Psaltis, Peter J. · 2024 · Journal of Clinical Medicine
  12. Effectiveness and safety of drugs for obesity
    Henderson Lewis, Kristina, Sloan, Caroline E, Bessesen, Daniel H, Arterburn, David · 2024 · BMJ
  13. Is Obesity or Adiposity-Based Chronic Disease Curable: The Set Point Theory, the Environment, and Second-Generation Medications
    Garvey, W. Timothy · 2022 · Endocrine Practice
  14. GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
    Daria Abasheva, Alberto Ortíz, Beatriz Fernández‐Fernández · 2024 · Clinical Kidney Journal
  15. Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US
    Chungsoo Kim, Joseph S. Ross, Ania M. Jastreboff, Daniella Meeker, Harry Freedman, Harlan M. Krumholz, Yuan Lu · 2025 · JAMA
  16. Prediabetes
    Ranjit Unnikrishnan I, Jonathan E. Shaw, Juliana C.N. Chan, Sarah H. Wild, Anne L. Peters, Sharon Orrange, Michael Roden, Viswanathan Mohan · 2025 · Nature Reviews Disease Primers
  17. Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
    Krüger, Nils, Schneeweiss, Sebastian, Fuse, Kenshiro, Matseyko, Sofiya, Sreedhara, Sushama Kattinakere, Hahn, Georg, Schunkert, Heribert, Wang, Shirley V. · 2025 · JAMA
  18. Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis
    Vosoughi, Kia, Salman Roghani, Roham, Camilleri, Michael · 2022 · Obesity Medicine
  19. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health
    Gilbert, Olivia, Gulati, Martha, Gluckman, Ty J., Kittleson, Michelle M., Rikhi, Rishi, Saseen, Joseph J., Tchang, Beverly G. · 2025 · JACC
  20. Efficacy and safety of semaglutide for weight management: evidence from the STEP program
    Anastassia Amaro, Danny H. Sugimoto, Sean Wharton · 2022 · Postgraduate Medicine
  21. Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
    Angelica Artasensi, Angelica Mazzolari, Alessandro Pedretti, Giulio Vistoli, Laura Fumagalli · 2023 · Molecules
  22. Evolving Paradigms of Recombinant Protein Production in Pharmaceutical Industry: A Rigorous Review
    Achuth Jayakrishnan, Wan Rosalina Wan Rosli, Ahmad Rashidi Mohamed Tahir, Fashli Syafiq Abd Razak, Phei Er Kee, Hui Suan Ng, Yik-Ling Chew, Siew-Keah Lee, Mahenthiran Ramasamy, Ching Siang Tan et al. · 2024 · Sci
  23. American Society for Gastrointestinal Endoscopy–European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity
    Pichamol Jirapinyo, Alia Hadefi, Vincent Huberty, Shelby A. Sullivan, Christopher C. Thompson, Árpád V. Patai, Rahul Pannala, Stefan Karl Goelder, Vladimir M. Kushnir, Marc A. Barthet et al. · 2024 · Endoscopy
  24. Glucagon-like peptide-1 receptor agonists and muscle mass effects
    Ceasovschih, Alexandr, Asaftei, Andreea, Lupo, Maria Giovanna, Kotlyarov, Stanislav, Bartušková, Hana, Balta, Anastasia, Sorodoc, Victorita, Sorodoc, Laurentiu, Banach, Maciej · 2025 · Pharmacological Research
  25. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study
    Johnson, Brittany, Milstead, Mary, Thomas, Olena, McGlasson, Tyler, Green, Lauren, Kreider, Rachel, Jones, Rachel · 2025 · Frontiers in Nutrition
  26. Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m 2 : SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy
    de Lemos, James A., Linetzky, Bruno, le Roux, Carel W., Laffin, Luke J., Vongpatanasin, Wanpen, Fan, Ludi, Hemmingway, Andrea, Ahmad, Nadia N., Bunck, Mathijs C., Stefanski, Adam · 2024 · Hypertension
  27. Implications of a New Obesity Definition Among the All of Us Cohort
    Lindsay T. Fourman, Aya Awwad, Alba Gutiérrez‐Sacristán, Camille A. Dash, Julia E Johnson, Allison K. Thistle, Nikhita Chahal, Sara L Stockman, Mabel P. Toribio, Chika Vera Anekwe et al. · 2025 · JAMA Network Open
  28. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
    Mandeep Singh Bajaj, Rozalina G. McCoy, Kirthikaa Balapattabi, Raveendhara R. Bannuru, Natalie J. Bellini, Allison K. Bennett, Elizabeth Ann Beverly, Kathaleen Briggs Early, Sathyavathi ChallaSivaKanaka, Justin Basile Echouffo-Tcheugui et al. · 2025 · Diabetes Care
  29. Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia
    Memel, Zoe, Gold, Stephanie L., Pearlman, Michelle, Muratore, Alicia, Martindale, Robert · 2025 · Current Nutrition Reports
  30. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906
    Jungnik, Arvid, Arrubla Martinez, Jorge, Plum‐Mörschel, Leona, Kapitza, Christoph, Lamers, Daniela, Thamer, Claus, Schölch, Corinna, Desch, Michael, Hennige, Anita M. · 2023 · Diabetes, Obesity and Metabolism
  31. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study
    Ji, Linong, Jiang, Hongwei, An, Pei, Deng, Huan, Liu, Meng, Li, Li, Feng, Liqi, Song, Baili, Han-Zhang, Han, Ma, Qingyang et al. · 2021 · EClinicalMedicine
  32. GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes
    Ramsey, David J., Makwana, Bhargav, Dani, Sourbha S., Patel, Manav, Panchal, Krisha, Shah, Jui, Khadke, Sumanth, Kumar, Ashish, Patel, Tirth, Kosiborod, Mikhail N. et al. · 2025 · JAMA Network Open
  33. The Function of Gastrointestinal Hormones in Obesity—Implications for the Regulation of Energy Intake
    Mona Farhadipour, Inge Depoortere · 2021 · Nutrients
  34. When fat meets the gut—focus on intestinal lipid handling in metabolic health and disease
    Magdalena Wit, Jonathan Trujillo Viera, Akim Strohmeyer, Martin Klingenspor, Mohammed K. Hankir, Grzegorz Sumara · 2022 · EMBO Molecular Medicine
  35. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
    Katharina Staufer, Rudolf E Stauber · 2023 · Biomedicines
  36. SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
    Bartosz Rolek, Mateusz Haber, Magdalena Gajewska, Sylwester Rogula, Arkadiusz Pietrasik, Aleksandra Gąsecka · 2023 · Journal of Cardiovascular Development and Disease
  37. Therapeutic advances in obesity management: an overview of the therapeutic interventions
    Moody Al Roomy, Kainat Hussain, Hawraa M. Behbehani, Jenna Abu-Farha, Rayan Al-Harris, Aishwarya Mariam Ambi, Mohammed Altigani Abdalla, Fahd Al‐Mulla, Mohamed Abu‐Farha, Jehad Ahmed Abubaker · 2024 · Frontiers in Endocrinology
  38. Semaglutide and blood pressure: an individual patient data meta-analysis
    Cormac Kennedy, Peter Clive Hayes, Arrigo F.G. Cicero, Stephan Dobner, Carel Wynand le Roux, John William McEvoy, Lina Zgaga, Martina Hennessy · 2024 · European Heart Journal
  39. Clinical practice guideline for the management of hypertension in China
    Chinese Society of Cardiology, Chinese Medical Association, Hypertension Committee of Cross-Straits Medicine Exchange Association, Cardiovascular Disease Prevention and Rehabilitation Committee, Chinese Association of Rehabilitation Medicine · 2024 · Chinese Medical Journal
  40. Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative Outcomes
    Seth Z. Aschen, Ashley Zhang, Gillian M. O’Connell, Sophia Salingaros, Caroline Andy, Christine Hsu Rohde, Jason A. Spector · 2024 · Annals of Surgery
  41. Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia.
    Siskind, Dan, Baker, Andrea, Arnautovska, Urska, Warren, Nicola, Russell, Anthony, DeMonte, Veronica, Halstead, Sean, Iyer, Ravi, Korman, Nicole, McKeon, Gemma et al. · 2025 · The Lancet Psychiatry
  42. Glucagon‐like peptide‐1 receptor agonists: a narrative review of clinical pharmacology and implications for peri‐operative practice
    Milder, David A., Milder, Tamara Y., Liang, Sophie S., Kam, Peter C.A. · 2024 · Anaesthesia
  43. Obesity in cystic fibrosis
    KATHERINE A. KUTNEY, Zahrae Sandouk, Marisa E. Desimone, Amir A. Moheet · 2021 · Journal of Clinical & Translational Endocrinology
  44. Intestinal Enteroendocrine Cells: Present and Future Druggable Targets
    Roger Atanga, Varsha Singh, Julie In · 2023 · International Journal of Molecular Sciences
  45. Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications
    Nomathemba C. Chandiwana, Mark Jacob Siedner, Vincent C. Marconi, Andrew Martin Hill, Mohammed Kumail Ali, Rachel Louise Batterham, François Venter · 2023 · The Journal of Clinical Endocrinology & Metabolism
  46. Phenotyping obesity: A focus on metabolically healthy obesity and metabolically unhealthy normal weight
    Rachel Agius, Nikolai Paul Pace, Stephen Fava · 2023 · Diabetes/Metabolism Research and Reviews
  47. Pharmacotherapy for obesity: moving towards efficacy improvement
    Walmir Ferreira Coutinho, Bruno Halpern · 2024 · Diabetology & Metabolic Syndrome
  48. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network
    David García‐Vega, David Sánchez-López, Gemma Rodríguez-Carnero, Rocío Villar‐Taibo, Juan E. Viñuela, Adán Lestegás-Soto, Ana Seoane‐Blanco, María Moure‐González, Susana B. Bravo, Ángel Luis Fernández et al. · 2024 · Cardiovascular Diabetology
  49. Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
    Gutgesell, Robert M., Nogueiras, Rubén, Tschöp, Matthias H., Müller, Timo D. · 2024 · Diabetes Therapy
  50. European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
    Stephan C. Bischoff, Rocco Barazzoni, Luca Busetto, Marjo J. E. Campmans-Kuijpers, Vincenzo Cardinale, Irit Chermesh, Ahad Eshraghian, Haluk Tarık Kani, Wafaa Khannoussi, L. Lacaze et al. · 2022 · Clinical Nutrition
  51. Obesity and Aging
    Noemi Malandrino, Salman Zahoor Bhat, Maha Alfaraidhy, Rajvarun S. Grewal, Rita Rastogi Kalyani · 2023 · Endocrinology and Metabolism Clinics of North America
  52. Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?
    Elena Domingo, Patrice Marqués, Vera Francisco, Laura Piqueras, María‐Jesús Sanz · 2024 · Pharmacological Research
  53. Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging
    Zainab Ridha, Sabrina Guillen Fabi, Raheel Zubair, Steven H. Dayan · 2024 · Aesthetic Surgery Journal
  54. Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss
    Mailhac, Aurélie, Pedersen, Lars, Pottegård, Anton, Søndergaard, Jens, Mogensen, Torben, Sørensen, Henrik, Thomsen, Reimar · 2024 · Clinical Epidemiology
  55. Postoperative Aspiration Pneumonia Among Adults Using GLP-1 Receptor Agonists
    Chen, Yuan-Hsin, Zink, Thomas, Chen, Ya-Wen, Nin, Darren Z., Talmo, Carl T., Hollenbeck, Brian L., Grant, Andrew R., Niu, Ruijia, Chang, David C., Smith, Eric L. · 2025 · JAMA Network Open
  56. Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa
    C Wendy Spearman, Mary Afihene, Omolade Betiku, Bilal Bobat, Lina Cunha, Chris Kassianides, Leolin Katsidzira, Hailemichael Desalegn, Ponsiano Ocama, Olusegun Ojo et al. · 2021 · The Lancet. Gastroenterology & hepatology
  57. Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations
    Nicolette Stogios, Bailey E. Humber, Sri Mahavir Agarwal, Margaret Hahn · 2023 · Current Psychiatry Reports
  58. Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management
    Giovanna Gallo, Giovambattista Desideri, Carmine Savoia · 2024 · Nutrients
  59. Updates on Methods for Body Composition Analysis: Implications for Clinical Practice
    Diana Maria Thomas, Ira Crofford, John Scudder, Brittany Oletti, Ashok Deb, SB Heymsfield · 2025 · Current Obesity Reports
  60. Obesity, Heart Failure with Preserved Ejection Fraction, and the Role of Glucagon-Like Peptide-1 Receptor Agonists
    Giuliana Cimino, Muthiah Vaduganathan, Carlo Lombardi, Matteo Pagnesi, Enrico Vizzardi, Daniela Tomasoni, Marianna Adamo, Marco Metra, Riccardo Maria Inciardi · 2023 · ESC Heart Failure
  61. Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
    Frederick Berro Rivera, Grace Nooriza O. Lumbang, Danielle Rose Magno Gaid, Linnaeus Louisse A. Cruz, John Vincent Magalong, Nathan Ross B. Bantayan, Kyla M. Lara-Breitinger, Martha Gulati, George L. Bakris · 2024 · Diabetes Obesity and Metabolism
  62. Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials
    Sarah Kanbour, Rwedah A Ageeb, Rayaz Ahmed Malik, Laith Jamal Abu-Raddad · 2025 · The Lancet Diabetes & Endocrinology
  63. Once-Weekly Semaglutide in Adults with Overweight or Obesity
    Eugen Javor, Marko Lucijanić, Marko Skelin · 2021 · New England Journal of Medicine
  64. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
    Reiss, Allison B., Gulkarov, Shelly, Lau, Raymond, Klek, Stanislaw P., Srivastava, Ankita, Renna, Heather A., De Leon, Joshua · 2025 · Biomolecules
  65. Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations
    Chao, Ariana M, Tronieri, Jena Shaw, Amaro, Anastassia, Wadden, Thomas A · 2022 · Drug Design, Development and Therapy
  66. Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction
    Elia C. El Hajj, Milad C. El Hajj, Brandon Sykes, Melissa Lamicq, Michael R. Zile, Robert Malcolm, Patrick M. O’Neil, Sheldon E. Litwin · 2021 · Journal of the American Heart Association
  67. Treating inflammation to combat non-alcoholic fatty liver disease
    Leke Wiering, Frank Tacke · 2022 · Journal of Endocrinology
  68. Unraveling Adipose Tissue Dysfunction: Molecular Mechanisms, Novel Biomarkers, and Therapeutic Targets for Liver Fat Deposition
    Marta Lopez‐Yus, Carlos Horndler, Sofía Borlán Ansón, Vanesa Bernal Monterde, José Miguel Arbonés-Mainar · 2024 · Cells
  69. GLP-1 programs the neurovascular landscape
    Bandy Chen, Xiaofei Yu, CLAUDIA HORVATH-DIANO, María José Ortuño, Matthias H. Tschöp, Ania M. Jastreboff, Marc Schneeberger · 2024 · Cell Metabolism
  70. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies
    Massimo Quarenghi, Silvia Capelli, Giulia Galligani, Arianna Giana, Giorgia Preatoni, Rosamaria Turri Quarenghi · 2025 · Journal of Clinical Medicine
  71. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
    Coskun, Tamer, Wu, Qiwei, Schloot, Nanette C, Haupt, Axel, Milicevic, Zvonko, Khouli, Courtney, Harris, Charles · 2025 · The Lancet Diabetes & Endocrinology
  72. Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
    Masson, Walter, Lobo, Martín, Nogueira, Juan Patricio, Rodriguez-Granillo, Alfredo Matias, Barbagelata, Leandro Ezequiel, Siniawski, Daniel · 2024 · Frontiers in Cardiovascular Medicine
  73. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
    Charlotte C. van Ruiten, Mark M. Smits, Megan D. Kok, Erik H. Serné, Daniël H. van Raalte, Mark H.H. Kramer, Max Nieuwdorp, Richard G. IJzerman · 2022 · Cardiovascular Diabetology
  74. Obesity
    Adam H. Gilden, Victoria A. Catenacci, John Michael Taormina · 2024 · Annals of Internal Medicine
  75. International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
    RICARDO VITOR COHEN, Luca Busetto, Randy S. Levinson, Carel Wynand le Roux, Paulina T. P. Salminen, Gerhard Prager, International Consensus on the Role of Obesity Management Medications in the Context of Metabolic Bariatric Surgery, Ali Aminian, Matthias Blüher, Lena M. S. Carlsson et al. · 2024 · British journal of surgery
  76. The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
    Ibrahim, Shahad Sabaawi, Ibrahim, Raghad Sabaawi, Arabi, Batoul, Brockmueller, Aranka, Shakibaei, Mehdi, Büsselberg, Dietrich · 2024 · Cancer and Metastasis Reviews
  77. Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
    Rubino, Domenica, Bjorner, Jakob B., Rathor, Naveen, Sharma, Arya M., von Huth Smith, Lisa, Wharton, Sean, Wadden, Thomas, Zeuthen, Niels, Kolotkin, Ronette L. · 2024 · Diabetes, Obesity and Metabolism
  78. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
    Kai Zhu, Rohan Kakkar, Daljeet Chahal, Eric M. Yoshida, Trana Hussaini · 2023 · World Journal of Gastroenterology
  79. Central Adiposity Increases Risk of Kidney Stone Disease through Effects on Serum Calcium Concentrations
    Catherine Elizabeth Lovegrove, Jelena Bešević, Akira Wiberg, Ben Lacey, Thomas J. Littlejohns, Naomi E. Allen, Michelle E. Goldsworthy, Jihye Kim, Fadil M. Hannan, Gary C. Curhan et al. · 2023 · Journal of the American Society of Nephrology
  80. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review
    Khalid M Hamed, Mohammed N Alosaimi, Bashaer A Ali, Atheer M. Alghamdi, Taif Alkhashi, Salman S Alkhaldi, Nawaf Abid Altowarqi, Hayat Alzahrani, Abdullah Alshehri, Rami K Alkhaldi et al. · 2024 · Cureus
  81. Tirzepatide for overweight and obesity management
    Malak Hamza, Dimitris Papamargaritis, Melanie Jane Davies · 2024 · Expert Opinion on Pharmacotherapy
  82. The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review
    Old, Victoria J., Davies, Melanie J., Papamargaritis, Dimitris, Choudhary, Pratik, Watson, Emma L. · 2025 · Journal of Cachexia, Sarcopenia and Muscle
  83. Suppression of food intake by Glp1r/Lepr-coexpressing neurons prevents obesity in mouse models
    Rupp, Alan C., Tomlinson, Abigail J., Affinati, Alison H., Yacawych, Warren T., Duensing, Allison M., True, Cadence, Lindsley, Sarah R., Kirigiti, Melissa A., MacKenzie, Alexander, Polex-Wolf, Joseph et al. · 2023 · Journal of Clinical Investigation
  84. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial
    Qin, Wenhui, Yang, Jun, Ni, Ying, Deng, Chao, Ruan, Qinjuan, Ruan, Jun, Zhou, Peng, Duan, Kai · 2024 · Endocrine
  85. The effects of GLP-1 agonists on musculoskeletal health and orthopedic care
    Gatto, Andrew, Liu, Kevin, Milan, Nesa, Wong, Stephanie · 2025 · Current Reviews in Musculoskeletal Medicine
  86. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial
    Eckard, Allison Ross, Wu, Qian, Sattar, Abdus, Ansari-Gilani, Kianoush, Labbato, Danielle, Foster, Theresa, Fletcher, Aaron A, Adekunle, Ruth O, McComsey, Grace A · 2024 · The Lancet Diabetes & Endocrinology
  87. GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons
    Georgios S. Papaetis, Angelos Kyriacou · 2022 · Advances in Clinical and Experimental Medicine
  88. High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine
    Esther Reijnders, Arnoud van der Laarse, J. Wouter Jukema, Christa M. Cobbaert · 2023 · Frontiers in Cardiovascular Medicine
  89. Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities
    Sahana Bettadapura, Katherine Dowling, Kelli L. Jablon, Ahmed W. Al-Humadi, Carel Wynand le Roux · 2024 · International Journal of Obesity
  90. Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety
    Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjær Jensen, Signe S. Torekov · 2024 · Obesity Reviews
  91. Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches
    Meghan D. Althoff, Kristina M. Gaietto, Fernando Holguín, Erick Forno · 2024 · American Journal of Respiratory and Critical Care Medicine
  92. Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease
    Jacob J. Gries, Jeffrey Victor Lazarus, Paul Brennan, Mohammad Shadab Siddiqui, Giovanni Targher, Chim Choy Lang, Salim S. Virani, Carl J. Lavie, Scott D. Isaacs, Juan Pablo Arab et al. · 2024 · The Lancet. Gastroenterology & hepatology
  93. Unmasking obstructive sleep apnea: Estimated prevalence and impact in the United States
    İbrahim Sönmez, Alexandre Vo Dupuy, Kristina S. Yu, John Cronin, John Yee, Ali Azarbarzin · 2025 · Respiratory Medicine
  94. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status
    Gasoyan, Hamlet, Butsch, W. Scott, Schulte, Rebecca, Casacchia, Nicholas J., Le, Phuc, Boyer, Christopher B., Griebeler, Marcio L., Burguera, Bartolome, Rothberg, Michael B. · 2025 · Obesity
  95. Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity
    Nicolau, Joana, Pujol, Antelm, Tofé, Santiago, Bonet, Aina, Gil, Apolonia · 2022 · Physiology & Behavior
  96. Glucagon-like Peptide-1 receptor agonist impact on chronic ocular disease including age-related macular degeneration
    Allan, Kevin C., Joo, Julia H., Kim, Sonia, Shaia, Jacqueline, Kaelber, David C., Singh, Rishi, Talcott, Katherine E., Rachitskaya, Aleksandra V. · 2025 · Ophthalmology
  97. Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States
    Lu, Yuan, Liu, Yuntian, Krumholz, Harlan M. · 2022 · Journal of the American Heart Association
  98. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
    Xie, Zeyu, Zheng, Guimei, Liang, Zhuoru, Li, Mengting, Deng, Weishang, Cao, Weiling · 2024 · Metabolism
  99. Current and future pharmacotherapies for obesity in children and adolescents
    Kelly, Aaron S. · 2023 · Nature Reviews Endocrinology
  100. Hormonal Gut–Brain Signaling for the Treatment of Obesity
    Eun Roh, Kyung Mook Choi · 2023 · International Journal of Molecular Sciences